Literature DB >> 15495255

Autoimmune cytopenias associated with autoantibodies to nuclear envelope polypeptides.

Paul Coppo1, Jean-Pierre Clauvel, Djaouida Bengoufa, Vincent Fuentes, Valérie Gouilleux-Gruart, Jean-Claude Courvalin, Kaiss Lassoued.   

Abstract

A subset of anti-nuclear autoantibodies (ANA) are directed against nuclear envelope (NE) polypeptides and display by indirect immunofluorescence (IIF) a ring-like fluorescent pattern. We report herein 19 patients with autoimmune cytopenias associated with antibodies (Abs) to NE polypeptides. Anti-NE specificity was determined by immunoblot, using NE preparations and purified lamina fractions. Eleven sera reacted with lamin B(1), and two reacted with both lamin B(1) and an unidentified 150-kDa protein (p150). One serum reacted with only p150. Four sera reacted with lamins A and C, and one reacted with and an unidentified 52-kDa NE polypeptide (p52). Autoimmune cytopenias included hemolytic anemia (7 cases), thrombocytopenia (13 cases), and neutropenia (6 cases). Five patients had 2 (3 cases) or 3 (2 cases) different cytopenias. Antiphospholipid antibodies (APLA) were detected in 14 patients, 2 of whom experienced thromboembolic events. A liver disorder was present in 7 patients. Systemic lupus erythematosus and lupus-like syndrome were diagnosed in 11 and 2 patients, respectively. Cytopenias responded to steroids alone (13 patients), or together with intravenous immunoglobulins (2 patients), or cyclophosphamide (2 patients). Two patients did not require treatment. Our results suggest that anti-NE Abs need to be sought for in patients with peripheral cytopenias, particularly when they are associated with APLA and/or liver disorders. Their detection strongly suggests an autoimmune process. Such cytopenias are often manifestations of a lupus or lupus-like disease and are responsive to steroids.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15495255     DOI: 10.1002/ajh.20188

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  6 in total

1.  Fibrosis and subsequent cytopenias are associated with basic fibroblast growth factor-deficient pluripotent mesenchymal stromal cells in large granular lymphocyte leukemia.

Authors:  Adam W Mailloux; Ling Zhang; Lynn Moscinski; John M Bennett; Lili Yang; Sean J Yoder; Gregory Bloom; Cody Wei; Sheng Wei; Lubomir Sokol; Thomas P Loughran; Pearlie K Epling-Burnette
Journal:  J Immunol       Date:  2013-09-06       Impact factor: 5.422

Review 2.  Primary biliary cirrhosis: what do autoantibodies tell us?

Authors:  Chao-Jun Hu; Feng-Chun Zhang; Yong-Zhe Li; Xuan Zhang
Journal:  World J Gastroenterol       Date:  2010-08-07       Impact factor: 5.742

Review 3.  Prevalence of secondary hematologic disorders in the antiphospholipid syndrome: impact on coagulation risk.

Authors:  Sharon L Kolasinski
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

4.  Optimized detection of circulating anti-nuclear envelope autoantibodies by immunofluorescence.

Authors:  Vagia Tsiakalou; Elena Tsangaridou; Hara Polioudaki; Artemissia-Phoebe Nifli; Meri Koulentaki; Tonia Akoumianaki; Elias Kouroumalis; Elias Castanas; Panayiotis A Theodoropoulos
Journal:  BMC Immunol       Date:  2006-09-06       Impact factor: 3.615

5.  Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective.

Authors:  Jan Damoiseaux; Luis Eduardo Coelho Andrade; Orlando Gabriel Carballo; Karsten Conrad; Paulo Luiz Carvalho Francescantonio; Marvin J Fritzler; Ignacio Garcia de la Torre; Manfred Herold; Werner Klotz; Wilson de Melo Cruvinel; Tsuneyo Mimori; Carlos von Muhlen; Minoru Satoh; Edward K Chan
Journal:  Ann Rheum Dis       Date:  2019-03-12       Impact factor: 19.103

6.  High COVID-19 virus replication rates, the creation of antigen-antibody immune complexes and indirect haemagglutination resulting in thrombosis.

Authors:  Kevin Roe
Journal:  Transbound Emerg Dis       Date:  2020-06-03       Impact factor: 4.521

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.